Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
250.04(c) 248.1(c) 253.33(c) 252.97(c) 250.8(c) Last
1 331 175 1 006 030 2 236 867 1 552 902 821 079 Volume
-0.02% -0.78% +2.11% -0.14% -0.86% Change
More quotes
Financials ($)
Sales 2017 11 387 M
EBIT 2017 5 829 M
Net income 2017 3 655 M
Finance 2017 296 M
Yield 2017 -
Sales 2018 12 037 M
EBIT 2018 6 389 M
Net income 2018 4 455 M
Finance 2018 2 698 M
Yield 2018 -
P/E ratio 2017 14,95
P/E ratio 2018 11,97
EV / Sales2017 4,65x
EV / Sales2018 4,20x
Capitalization 53 198 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
05/31 | 09:00pmPresentation
More about the company
Surperformance© ratings of Biogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN INC
05/24 BIOGEN : ’s FAMPYRA® Granted Standard Marketing Authorization in European ..
05/18 BIOGEN : Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™
05/17 BIOGEN : to Present at the Bernstein 33rd Annual Strategic Decisions Conference
05/15 BIOGEN : Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemisphe..
04/25DJNasdaq Composite Tops 6000 for First Time
04/25 BIOGEN : Reports First Quarter 2017 Revenues of $2.8 Billion
04/24 BIOGEN : TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early M..
04/21 BIOGEN : SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment..
04/18 BIOGEN : Highlights Advances from Its Neurology Research Programs and Portfolio ..
03/28 BIOGEN : to Present Data at the 13th International Conference on Alzheimer&rsquo..
More news
Sector news : Biopharmaceuticals
06:49p WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
06:41pDJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN INC 
2014Back on a stimulating support
2013The bullish trend is not over
More Strategies
Latest Tweets
06:30pFavorable Press Coverage Very Likely to Impact Biogen $BIIB Share Price  
02:53pNew Mexico Educational Retirement Board Has $5.981 Million Position in Biogen.. 
02:52pWellington Shields Capital Management LLC Has $1,154,000 Stake in Biogen Inc .. 
05/27Biogen Inc $BIIB Shares Bought by Henderson Group PLC  
05/27Girard Partners LTD. Boosts Stake in Biogen Inc $BIIB  
More tweets
Qtime:131
News from SeekingAlpha
05/26 Time For Tau - For Now
05/26 STOCK EXCHANGE : Time to reconsider health care?
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/24 Roche investigating brain infection in Ocrevus patient
05/24 BBP : A Diversified Biotech ETF
Advertisement
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 318 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-4.03%53 198
CSL LIMITED31.55%44 709
ALEXION PHARMACEUTICAL..-20.15%21 939
GRIFOLS SA31.81%17 451
BIOMARIN PHARMACEUTICA..6.23%15 355
CHONGQING ZHIFEI BIOLO..--.--%4 238
More Results